Chinese biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the updated 2024 National Reimbursement Drug List (NRDL) now incudes SINTBILO (tafolecimab injection, an anti-PCSK9 monoclonal antibody) for the first time, along with a new indication for olverembatinib (a BCR-ABL inhibitor).

The updated NRDL will be effective from 1 January 2025.

SINTBILO is newly listed for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial types) and mixed dyslipidaemia. SINTBILO is Innovent's first entry into the cardiovascular field, offering multiple dosing options: 150mg Q2W, 450mg Q4W and 600mg Q6W. These regimens significantly reduce low-density lipoprotein cholesterol (LDL-C) levels by nearly 70% and lower lipoprotein a [Lp(a)] by nearly 50%. As the first domestic PCSK9 inhibitor in the NRDL, SINTBILO provides a new treatment option for cholesterol management in China, improving quality of life for a broad population of patients with hypercholesterolemia.

Dr. Michael Yu, Innovent founder, chairman and CEO, said: "We are pleased with the inclusion of SINTBILO in the NRDL, which will significantly increase the accessibility and affordability of this innovative therapy and marks a significant achievement for both Innovent and patients with hypercholesterolemia. We are also encouraged by the inclusion of the new indication of olverembatinib in the NRDL, which will benefit a broader range of CML patients."